Last update 08 May 2025

Valganciclovir Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cymeval, Valganciclovir, Valganciclovir hydrochloride (JAN/USP)
+ [21]
Action
inhibitors
Mechanism
DNA-directed DNA polymerase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Mar 2001),
RegulationOrphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H23ClN6O5
InChIKeyZORWARFPXPVJLW-MTFPJWTKSA-N
CAS Registry175865-59-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Virus Diseases
China
13 Dec 2005
Acquired Immunodeficiency Syndrome
Japan
05 Nov 2004
Cytomegalovirus Infections
Australia
17 Jun 2002
Cytomegalovirus Retinitis
United States
29 Mar 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hearing Loss, SensorineuralPhase 2
United States
31 Aug 2018
Chronic Lymphocytic LeukemiaPreclinical
United States
01 Sep 2003
Human herpesvirus 8 infectionPreclinical
United States
01 Dec 2002
Cytomegalovirus InfectionsPreclinical
United States
01 Nov 2001
Peripheral Stem Cell TransplantationPreclinical
United States
01 Nov 2001
Acquired Immunodeficiency SyndromePreclinical
Puerto Rico
31 Aug 2001
Acquired Immunodeficiency SyndromePreclinical
United States
31 Aug 2001
Cytomegalovirus RetinitisPreclinical
Canada
01 Jan 1997
Cytomegalovirus RetinitisPreclinical
United States
01 Jan 1997
HIV InfectionsPreclinical
Canada
01 Jan 1997
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
dpwrcqcnrk(retacqlemf) = most Grade 3-4 TRAEs have been haematologic in nature and generally manageable or reversible with only one Grade 5 TRAE bzsxefltmi (duaxkrftxv )
-
04 Sep 2024
Phase 2
137
jfrngntcij(dtaplawhcb) = aaksgwbdpk hfnshbozzp (jpboohmtgr )
Positive
01 Jun 2024
Valganciclovir
jfrngntcij(dtaplawhcb) = cbtqinfvti hfnshbozzp (jpboohmtgr )
Not Applicable
Glioblastoma
Add-on
MGMT methylation status | IDH1 wt
220
ieuxzbjcuz(rvqsrtrkqv) = Five patients showed reversible hematological side effects grade 3-4, always with the initial high dose and concomitant to radiochemotherapy. No patient stopped the study due to side effects. nrywnedavb (dxsakiwerk )
Positive
08 Sep 2023
Placebo
Phase 3
-
-
wgiyqvngoi(ymchrdfzzn) = jnskudwevx rvhjlipfjf (udkxtnipfh )
-
03 Jul 2023
wgiyqvngoi(ymchrdfzzn) = mvedqhoaxd rvhjlipfjf (udkxtnipfh )
Not Applicable
33
jmswiapxgu(zwdqjwxqrm) = otbhrmmnio pipicqashp (njplugfryl, 311.24–826.25)
-
15 Jun 2023
AACR2023
ManualManual
Phase 1
15
(qgehuqtrfv) = zsrdeofsvh fqhpycikpg (agagvnwjog )
Positive
14 Apr 2023
Not Applicable
Cytomegalovirus Infections
CMV IgG | CMV IgM | CMV DNA
32
uawhpssitc(gguonxvtvk) = rftdweshxo efarknxfac (ditxksizur )
Negative
01 Mar 2023
(No prophylaxis)
uawhpssitc(gguonxvtvk) = hdzdgqxbtq efarknxfac (ditxksizur )
Not Applicable
140
uodpeexwfu(jafbstzgns) = dsxawujnjg mduogwxwgb (zldlcmxeqm )
-
02 Feb 2023
Preemptive therapy
uodpeexwfu(jafbstzgns) = swlujdmtsl mduogwxwgb (zldlcmxeqm )
Phase 2
7
wakyqbsryt(fmwvxvwonl) = zljpixrbsj tfkoiycvmx (mytvorlgrz, wxxdlmasyc - lhkpawenyt)
-
26 Jan 2023
Not Applicable
-
(Neutropenic KTRs)
lfhkxmatoq(ycbkforhgw) = xejniazjld asqprzpsiu (bbaqplmghs )
-
04 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free